From: FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort
Responses
No. of patients
%
Complete response
1
1.4
Partial response
15
21.4
Stable disease
21
30
Progressive disease
33
47.2